|
Name |
(-)-4,6'-Anhydrooxysporidinone
|
| Molecular Formula | C28H41NO5 | |
| IUPAC Name* |
(5aR,9aS)-4-[(2S,5R,6R)-6-[(E)-4,6-dimethyloct-2-en-2-yl]-5-methyloxan-2-yl]-9a-hydroxy-2-methyl-5a,6,8,9-tetrahydro-[1]benzofuro[3,2-c]pyridine-3,7-dione
|
|
| SMILES |
CCC(C)CC(C)/C=C(\C)/[C@H]1[C@@H](CC[C@H](O1)C2=C3C(=CN(C2=O)C)[C@]4(CCC(=O)C[C@H]4O3)O)C
|
|
| InChI |
InChI=1S/C28H41NO5/c1-7-16(2)12-17(3)13-19(5)25-18(4)8-9-22(33-25)24-26-21(15-29(6)27(24)31)28(32)11-10-20(30)14-23(28)34-26/h13,15-18,22-23,25,32H,7-12,14H2,1-6H3/b19-13+/t16?,17?,18-,22+,23-,25-,28+/m1/s1
|
|
| InChIKey |
HIEAPHJQEBHMLL-YKXVSDKYSA-N
|
|
| Synonyms |
(-)-4,6'-anhydrooxysporidinone
|
|
| CAS | NA | |
| PubChem CID | 16109804 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 471.6 | ALogp: | 3.4 |
| HBD: | 1 | HBA: | 5 |
| Rotatable Bonds: | 6 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 76.1 | Aromatic Rings: | 4 |
| Heavy Atoms: | 34 | QED Weighted: | 0.568 |
| Caco-2 Permeability: | -4.718 | MDCK Permeability: | 0.00001430 |
| Pgp-inhibitor: | 0.982 | Pgp-substrate: | 0.589 |
| Human Intestinal Absorption (HIA): | 0.014 | 20% Bioavailability (F20%): | 0.014 |
| 30% Bioavailability (F30%): | 0.964 |
| Blood-Brain-Barrier Penetration (BBB): | 0.705 | Plasma Protein Binding (PPB): | 90.46% |
| Volume Distribution (VD): | 1.991 | Fu: | 2.95% |
| CYP1A2-inhibitor: | 0.033 | CYP1A2-substrate: | 0.841 |
| CYP2C19-inhibitor: | 0.392 | CYP2C19-substrate: | 0.95 |
| CYP2C9-inhibitor: | 0.494 | CYP2C9-substrate: | 0.763 |
| CYP2D6-inhibitor: | 0.01 | CYP2D6-substrate: | 0.371 |
| CYP3A4-inhibitor: | 0.701 | CYP3A4-substrate: | 0.883 |
| Clearance (CL): | 8.127 | Half-life (T1/2): | 0.096 |
| hERG Blockers: | 0.109 | Human Hepatotoxicity (H-HT): | 0.946 |
| Drug-inuced Liver Injury (DILI): | 0.334 | AMES Toxicity: | 0.064 |
| Rat Oral Acute Toxicity: | 0.949 | Maximum Recommended Daily Dose: | 0.952 |
| Skin Sensitization: | 0.138 | Carcinogencity: | 0.069 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.008 |
| Respiratory Toxicity: | 0.905 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC002822 | ![]() |
0.781 | D0W2EK | ![]() |
0.247 | ||
| ENC004957 | ![]() |
0.547 | D02IQY | ![]() |
0.225 | ||
| ENC003476 | ![]() |
0.538 | D04JHN | ![]() |
0.224 | ||
| ENC003004 | ![]() |
0.538 | D0I2SD | ![]() |
0.220 | ||
| ENC005829 | ![]() |
0.508 | D0L7AS | ![]() |
0.219 | ||
| ENC004958 | ![]() |
0.376 | D0X5KF | ![]() |
0.219 | ||
| ENC002816 | ![]() |
0.314 | D06YFA | ![]() |
0.218 | ||
| ENC004573 | ![]() |
0.310 | D05AFC | ![]() |
0.217 | ||
| ENC003638 | ![]() |
0.296 | D03SKD | ![]() |
0.215 | ||
| ENC003489 | ![]() |
0.289 | D0PG8O | ![]() |
0.215 | ||